NCT01783756View on ClinicalTrials.gov

Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 26, 2013

Primary Completion Date

May 10, 2019

Study Completion Date

May 10, 2019

Conditions
Central Nervous System MetastasesHER2-positive Breast CancerMale Breast CancerRecurrent Breast CancerStage IV Breast Cancer
Interventions
DRUG

lapatinib ditosylate

Given PO

DRUG

everolimus

Given PO

DRUG

capecitabine

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

90095

Jonsson Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
lead

Jonsson Comprehensive Cancer Center

OTHER

NCT01783756 - Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis | Biotech Hunter | Biotech Hunter